Treatment of Heart Failure in Infants and Children

Heart Disease

Volumn 2, Issue 5, 2000, Pages 354-361

  Clark III, Bernard J ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC BETA ANTAGONISTS; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; SPIRONOLACTONE;

CHILD; CONGESTIVE HEART FAILURE; FEMALE; HUMAN; INFANT; MYOCARDITIS; NEWBORN; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; DIGOXIN; DIURETICS; FEMALE; HEART FAILURE, CONGESTIVE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; MYOCARDITIS; SPIRONOLACTONE;

EID: 0034281279     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Balaguru D, Artman M, Auslender M. Management of heart failure in children. Curr Probl Pediatr 2000;12:5-30.
2. Cohn JN. Drug Therapy. The management of chronic heart failure. N Engl J Med 1996;335:490-498.
3. Gheorghiade M, Cody RJ, Francis GS, et al. Current medical therapy for advanced heart failure. Heart Lung 2000;29:16-32.
4. O'Laughlin MP. Congestive heart failure in children. Pediatri Clin North Am 1999;46:263-273.
5. Gajarski RJ, Towbin JA. Recent advances in the etiology, diagnosis, and treatment of myocarditis and cardiomyopathies in children. Curr Opin Pediatr 1995; 7:587-594.
6. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med 1994;330: 913-919.
7. Arola A, Tuominen J, Ruuskanen O, et al. Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics 1998;101:369-376.
8. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol 1992;69:1458-1466.
9. Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adlescents. A nationwide study in Finland. Am J Epidemiol 1997;146:385-393.
10. Venugopalan P, Agarwal AK, Akinbami FO, et al. Improved prognosis of heart failure due to idiopathic dilated cardiomyopathy in children. Intl J Cardiol 1998;65:125-128.
11. Akagi T, Benson LN, Lightfoor Ne, et al. Natural history of dilated cardiomyopathy in children. Am Heart J 1991;121:1502-1506.
12. Burch M, Siddiqi SA, Celermajer DS, et al. Dilated cardiomyopathy in children: determinants of outcome. Br Heart J 1994;72:246-250.
13. Griffin ML, Hernandez A, Martin TC, et al. Dilated cardiomyopathy in infants and children. J Am Coll Cardiol 1988;11:139-144.
14. Lewis AB, Chabot M. Outcome of infants and children with dilated cardiomyopathy. Am J Cardiol 1991;68:365-369.
15. Lewis AB. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy. American Heart Journal 1999;138:334-338.
16. Yang S.-G., Clark BJ, Bridges ND. Evaluation and management of children with end stage cardiomyopathy and elevated pulmonary vascular resistance. Paper presented at: 18th Annual Scientific Meeting of the American Society of Transplant Physicians; May 1999; Chicago, IL.
17. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7.
18. Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1995;55:623-630.
19. Young J. Heart failure: highlights from new consensus guidelines. Cleve Clin J Med 2000;67:13-26.
20. Berman W, Yabek SM, Dillon T, et al. Effects of digoxin in infants with congested circulatory state due to a ventricular septal defect. N Engl J Med 1983; 308:363-366.
21. Kimball TR, Daniels SR, Meyer RA, et al. Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am J Cardiol 1991; 68:1377-1382.
22. Nony P, Boissel JP, Girard P, et al. Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: Implications of randomized trials and role of the etiology (ischaemic or nonischaemic) of heart failure. Eur Heart J 1992;13:1101-1108.
23. Packer M, Lee WH, Yushak M, et al. Comparison of captopril and enalapril in-patients with severe chronic heart failure. N Engl J Med 1986;315:847-853.
24. Swedberg K, Held P, Kjekhus J, et al. Effects of the early administrator of enalapril on mortality in patients with acute myocardial infarction - Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-684.
25. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
26. Brown NJ, Vaughn DE. Angiotensin converting enzyme inhibitors. Circulation 1998;97:1411-1420.
27. Montigny M, Davignon A, Fouron JC, et al. Captopril in infants for congestive heart failure secondary to a large ventricular left-to-right shunt. Am J Cardiol 1989;63:631-633.
28. Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child 1988;63:360-363.
29. Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 1991;83:523-527.
30. Lewis AB, Chabot M. The effect of treatment with angiotensin converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993;14:9-12.
31. Alehan D, Ozkutlu S. Beneficial effects of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms. Am Heart J 1998; 135:598-603.
32. Lipshultz SE, Colan SD, Mone SM, et al. Afterload reduction therapy in long term survivors of childhood cancer treated with doxorubicin. Circulation 1991; 84:659.
33. Jalil JE, Janicki JS, Pick R, et al. Fibrillar collagen and myocardial stiffness in intact hypertrophied rat left ventricle Circ Res 1989;64:1041-1050.
34. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-2296.
35. Swedberg K, Hjalmarson A, Waagstein F, et al. Beneficial effects of long term beta-blockade in congestive cardiomyopathy. Am J Cardiol 1985;55:471-475.
36. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-475.
37. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-546.
38. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
39. CIBIS Investigators and Committees. A randomized trial of (beta)-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
40. Sponer G, Strein K, Muller-Beckman B, et al. Studies on the mode of vasodilating action of carvedilol. J Cardiovasc Pharmacol 1987;10(Suppl 1):S42-S48.
41. Gilbert EM, Anderson JL, Deitchman D. Long-term (beta)-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy. a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88: 223-229.
42. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334: 1349-1355.
43. Buchhorn R, Bartmus D, Siekmeyer W, et al. Beta blocker therapy of serve congestive heart failure with left to right shunts. Am J Cardiol 1998;81:1366-1368.
44. Shaddy RE. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 1998;136:19-21.
45. Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999;18:269-274.
46. Klug D, Rober V, Swynghedauw D. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993;71(Suppl):45A-54A.
47. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study. N Engl J Med 1999;341:709-717.
48. Borghi C, Boschi S, Ambrosioni E, et al. Evidence of a partial of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-45.
49. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;91:457-465.
50. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997;95:2476-2478.
51. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994;89:252-257.
52. Kleinert S, Weintraub RG, Wilkinson L, et al. Myocarditis in children with dilated cardiomyopathy: incidence and outcome after dual therapy immunosuppression. J Heart Lung Transplant 1997;16:1248-1254.
53. Mason JW, O'Connell JB, Herskowitz A, et al. A Clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333:269-275.
54. Garg A, Shiau J, Guyatt G. The ineffectiveness of immunosuppressive therapy in lymphocytic myocarditis. An overview. Ann Intern Med 1998;129:317-322.
55. Stolf NA, Morcira LF, Bocchi EA, et al. Determinents of midterm outcome of partial left ventriculectomy in dilated cardiomyopathy. Ann Thorac Surg 1998; 66:1585-1591.
56. Isomura T, Suma H, Horii T, et al. The Batista operation in patients with dilated cardiomyopathy. J Cardiac Surg 1999;14:124-128.
57. Batista RJV, Santos JVL, Takeshita N, et al. Partial ventriculectomy to improve left ventricular function in end-stage heart disease. J Cardiac Surg 1996;11:96-97.
58. Berger S, Tweddell JS, Frommelt PC, et al. Partial ventriculectomy for dilated cardiomyopathy in a newborn. J Thorac Cardiovasc Surg 1999;117:1017-1018.
59. Yoshi S, Hosaka S, Takahashi W, et al. Partial ventriculectomy in an infants with dilated cardiomyopathy. J Thorac Cardiovasc Surgery 1999;117:622-623.
60. Del Nido PJ. Editorial: partial left ventriculectomy for dilated cardiomyopathy in children. J Thorac Cardiovasc Surgery 1999;117:918-919.
61. Pennington DG, Swartz MT. Circulatory support in infants and children. Ann Thorac Surg 1993;55:233-237.
62. Marelli D, Laks H, Meehan DA, et al. Minimally invasive mechanical cardiac support without extracorporeal membrane oxygenation in children awaiting heart transplantation. Ann Thorac Surg 1999;68:2320-2323.
63. Di Russo GB, Clark BJ, Bridges ND, et al. Prolonged extracorporeal membrane oxygenation as a bridge to cardiac transplantation. Ann Thorac Surgery 2000; 69:925-927.